Moleculariy targeted agents against solar UV signal transduction pathways can be incorporated into topical formulations engineered to optimize delivery to skin and maximize the probability of success in preclinical and clinical evaluation. Long-term preclinical carcinogenesis studies in Projects 1-2 and dinical trials in Project 3 cannot be initiated without the preparation and proper testing of well-characterized, stable formulations of topical agents. The objective ofthe Drug Development Core is to efficiently design, prepare, test, and provide pharmaceutically suitable topical formulations of new skin cancer chemopreventive agents to Program Project investigators and to provide regulatory support for clinical development of candidates that show promise. Additionaly, the core provides the ability and expertise to synthesize new chemical entities as prodrugs or analogues in order to manipulate solubility, absorption, and delivery to the epidermis. This objective will be accomplished by the following Specific Aims: 1) To prepare stable formulations of promising new agents that can be effectively delivered to the epidermis following topical application, 2) To prepare batch formulations for long-term carcinogenesis studies in vivo and perform necessary preclinical toxicology, pharmacokinetic, and stability studies, and 3) To coordinate and prepare Investigational New Drug (IND) applications for FDA approval, and supervise production and distribution of clinical-grade supply for human trials in Project 3. The Core will oversee all aspects of topical agent preparation, formulation, and supply for each of the Projects. Quality control and assurance methods developed by the Drug Development Core in consultation with the Biometry Core will ensure regulatory compliance and enhance efficiency. The Core will work closely with each Project to provide necessary and appropriate preformualtion and topical formulations for each stage of mechanistic and efficacy studies in vivo. This will allow us to circumvent problems with epidermal delivery that normally hinder development of otherwise promising topical agents, and optimize the crucial selection criteria for advancement of new agents to clinical testing. This will greatly enhance our ability to translate basic science discoveries into new skin cancer chemopreventive drugs. This highly interactive and clinically translational research progrann project focuses on the successful preclinical testing of targeted chemoprevention agents in innovative mouse models (Projects 1 and 2) followed by the design and implementation of clinical trials in at risk human populations (Project 3). Detailed descriptions ofthe decision-tree selection process as well as the interactions between Projects and Cores are found on the Resources Format Page.

Public Health Relevance

The Drug Development Core will provide the required topical formulation, safety and regulatory activities necessary to translate the active chemical entities identified from the basic science Projects 1 and 2 into clinical studies developed and performed by Project 3.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Program Projects (P01)
Project #
5P01CA027502-31
Application #
8689921
Study Section
Special Emphasis Panel (ZCA1-GRB-P)
Project Start
Project End
Budget Start
2014-07-01
Budget End
2015-06-30
Support Year
31
Fiscal Year
2014
Total Cost
$158,940
Indirect Cost
$57,671
Name
University of Arizona
Department
Type
DUNS #
806345617
City
Tucson
State
AZ
Country
United States
Zip Code
85721
Dickinson, Sally E; Rusche, Jadrian J; Bec, Sergiu L et al. (2015) The effect of sulforaphane on histone deacetylase activity in keratinocytes: Differences between in vitro and in vivo analyses. Mol Carcinog 54:1513-20
Glazer, Evan S; Hornbrook, Mark C; Krouse, Robert S (2014) A meta-analysis of randomized trials: immediate stent placement vs. surgical bypass in the palliative management of malignant biliary obstruction. J Pain Symptom Manage 47:307-14
Williams, Joshua D; Bermudez, Yira; Park, Sophia L et al. (2014) Malondialdehyde-derived epitopes in human skin result from acute exposure to solar UV and occur in nonmelanoma skin cancer tissue. J Photochem Photobiol B 132:56-65
Sheng, Yuqiao; Li, Wei; Zhu, Feng et al. (2014) 3,6,2',4',5'-Pentahydroxyflavone, an orally bioavailable multiple protein kinase inhibitor, overcomes gefitinib resistance in non-small cell lung cancer. J Biol Chem 289:28192-201
Lim, Tae-Gyu; Lee, Sung-Young; Huang, Zunnan et al. (2014) Curcumin suppresses proliferation of colon cancer cells by targeting CDK2. Cancer Prev Res (Phila) 7:466-74
Wen, W; Peng, C; Kim, M O et al. (2014) Knockdown of RNF2 induces apoptosis by regulating MDM2 and p53 stability. Oncogene 33:421-8
Lim, Do Young; Lee, Mee-Hyun; Shin, Seung Ho et al. (2014) (+)-2-(1-Hydroxyl-4-oxocyclohexyl) ethyl caffeate suppresses solar UV-induced skin carcinogenesis by targeting PI3K, ERK1/2, and p38. Cancer Prev Res (Phila) 7:856-65
Yao, Ke; Chen, Hanyong; Liu, Kangdong et al. (2014) Kaempferol targets RSK2 and MSK1 to suppress UV radiation-induced skin cancer. Cancer Prev Res (Phila) 7:958-67
Dickinson, Sally E; Olson, Erik R; Levenson, Corey et al. (2014) A novel chemopreventive mechanism for a traditional medicine: East Indian sandalwood oil induces autophagy and cell death in proliferating keratinocytes. Arch Biochem Biophys 558:143-52
Franklin, Stephen J; Dickinson, Sally E; Karlage, Kelly L et al. (2014) Stability of sulforaphane for topical formulation. Drug Dev Ind Pharm 40:494-502

Showing the most recent 10 out of 348 publications